Cite
HARVARD Citation
Ailawadhi, S. et al. (2022). Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results. Hematological oncology. 40 (4), pp. 695-703. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Ailawadhi, S. et al. (2022). Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results. Hematological oncology. 40 (4), pp. 695-703. [Online].